Shares of Valeo Pharma Inc. (TSE:VPH – Get Free Report) dropped 14.3% during trading on Wednesday . The stock traded as low as C$0.06 and last traded at C$0.09. Approximately 127,381 shares traded hands during mid-day trading, an increase of 133% from the average daily volume of 54,677 shares. The stock had previously closed at C$0.11.
Valeo Pharma Trading Up 11.8 %
The company has a market capitalization of C$9.37 million, a price-to-earnings ratio of -0.30 and a beta of 2.56. The stock’s fifty day simple moving average is C$0.17 and its 200-day simple moving average is C$0.19.
Valeo Pharma (TSE:VPH – Get Free Report) last released its earnings results on Thursday, March 14th. The company reported C($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of C($0.08). The business had revenue of C$13.54 million for the quarter, compared to analyst estimates of C$15.30 million.
About Valeo Pharma
Valeo Pharma Inc, a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma.
Read More
- Five stocks we like better than Valeo Pharma
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Where Do I Find 52-Week Highs and Lows?
- Alphabet Changes the Narrative with Its First-Ever Dividend
- Investing in Commodities: What Are They? How to Invest in Them
- 5 High-Yielding Oversold Stocks with Bullish Ratings
Receive News & Ratings for Valeo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.